Orthocell CEO & Managing Director, Paul Anderson, explains the unique technology behind the company’s cellular regenerative medicine, and in particular how its collagen-based scaffold is different to other collagen therapies.
Orthocell shares surge after getting US patent
Orthocell has been featured in The Australian following news of securing a US patent for our “cell factory” technology.
Orthocell has positive tennis elbow result
Orthocell has been featured in The Australian’s Business Spectator, following the release of new positive results from a study of our tendon cell treatment for tennis elbow.
Funding boost for tendon research
The Australian has featured news of Orthocell’s Australian Research Council grant to continue its tendon research.
Patent success a good sign for Orthocell
Following our recent patent announcement, the Australian Financial Review has featured Orthocell in its Market Wrap.
Strong demand for biotech
The Australian newspaper has featured news of Orthocell’s listing on the ASX.
Biotech Orthocell looks to raise $8m in IPO
Details of Orthocell’s upcoming launch on the ASX has been featured in the Australian Financial Review (AFR).
Orthocell to list on ASX
Orthocell’s plans to list on the Australian Stock Exchange (ASX) have been featured in The Australian newspaper.
Stem cells show promise mending busted tendons
Jill Margo, Health Editor at the Australian Financial Review, has published a feature article on Orthocell’s innovative autologous tenocyte implantation (ATI) therapy.